Dendritic cells can prime anti-tumor CD8+ T cell responses through major histocompatibility complex cross-dressing
Open accessIntegrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Two recent publications describe a novel role for cancer cells and their type I IFN production in priming CD8+ T cell responses through MHC class I dressing of dendritic cells.
“This notion is further supported by two recent publications describing a novel role for cancer cells and their type I IFN production in priming CD8+ T cell responses through MHC class I dressing of dendritic cells49,62.”
From Epigenetic state determines the in vivo efficacy of STING agonist therapy (2023) · cites this paper as [62]
Cited by
Sorted by citations
Epigenetic state determines the in vivo efficacy of STING agonist therapy
Falahat, R., Berglund, A., Perez-Villarroel, P., Putney, R. M., Hamaidi, I., Kim, S., Pilon-Thomas, S., Barber, G. N., & Mulé, J. J. (2023) · Nature Communications · doi:10.1038/s41467-023-37217-1 · Cited by 94 · see citing works
- Authors
- MacNabb, B. W., Chen, X., Tumuluru, S., Godfrey, J., Kasal, D. N., Yu, J., Jongsma, M. L. M., Spaapen, R. M., Kline, D. E., & Kline, J.
- Corresponding author
- Kline, Douglas E.
- Kline, Justin
- ORCID
- Venue
- Immunity
- Publisher
- Elsevier BV
- Published
- 2022-11
- Volume
- 55
- Issue
- 11
- Pages
- 2206-2208
- ISSN
- 1074-7613 (ISSN-L)
- PMC
- PMC9885954
- OpenAlex
- W4308510430
- Cited by
- 35
- References
- 0
- Citations by year
- 2026: 11 · 2025: 9 · 2024: 9 · 2023: 5 · 2022: 1
- FWCI
- 2.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 568 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- Immunity (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA166770)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- dendritic cells, MHC class I, CD8+ T cell priming, antitumor immunity, antigen presentation, T cell activation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
